Eyeing The Future: AstraZeneca Farms Out Compounds To Ocular Specialist Alcon
This article was originally published in The Pink Sheet Daily
Executive Summary
Alcon's now-tenuous relationship with Novartis is unlikely to affect the new five-year research agreement with AstraZeneca.
You may also be interested in...
Novartis Secures Ophthalmic Diversity With Final Alcon Buyout
Novartis' new eye care division, created by folding together Alcon, CIBA Vision and some of the Swiss pharma's own ophthalmic therapies, will control more than 70 percent of the global eye care market at its inception. And it has a range of pipeline projects in the works to support that hegemony going forward
Novartis Secures Ophthalmic Diversity With Final Alcon Buyout
Novartis' new eye care division, created by folding together Alcon, CIBA Vision and some of the Swiss pharma's own ophthalmic therapies, will control more than 70 percent of the global eye care market at its inception. And it has a range of pipeline projects in the works to support that hegemony going forward
Eli Lilly Hires AstraZeneca's Jan Lundberg To Replace Steve Paul As Head Of R&D
The move comes amid a vast R&D reorganization at Lilly which, like AstraZeneca, is laboring to speed compounds into and through development.